Would you consider using bevacizumab/atezolizumab in HCC patients who received TKI in the first line?
Community PollStarted
What 2nd line therapy do you recommend for an HCC patient with Child Pugh Class A liver function after failure of a front-line single agent TKI?
93 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Memorial Sloan Kettering Cancer Center
Answered on
This is a great question. After failure of a front-line single agent TKI, I would still favor the current FDA-approved agents: regorafenib; cabozantinib; ramucirumab in AFP-high; OR immunotherapy (nivolumab, pembrolizumab, OR nivolumab plus ipilimumab).
It is important to note that the second-line ...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Rutgers Cancer Institute of New Jersey
Answered on
This is absolutely appropriate. The combination is highly active and should work after a multi TKI. But the data exist only for CP-A and those who had esophageal varices controlled with a recent endoscopy. Be aware of the potential for (fatal) GI bleeding. A study in B7 (The AB7) study will be condu...
Join for free or sign in to see the full answer